JP7042254B2 - 近赤外光開裂性コンジュゲートおよびコンジュゲート前駆体 - Google Patents

近赤外光開裂性コンジュゲートおよびコンジュゲート前駆体 Download PDF

Info

Publication number
JP7042254B2
JP7042254B2 JP2019506725A JP2019506725A JP7042254B2 JP 7042254 B2 JP7042254 B2 JP 7042254B2 JP 2019506725 A JP2019506725 A JP 2019506725A JP 2019506725 A JP2019506725 A JP 2019506725A JP 7042254 B2 JP7042254 B2 JP 7042254B2
Authority
JP
Japan
Prior art keywords
conjugate
alkyl
independently
drug
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019506725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524798A (ja
JP2019524798A5 (https=
Inventor
マーティン ジョン シュナーマン，
ロジャー ラウハウザー ナニ，
アレクサンダー パトリック ゴーカ，
久隆 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2019524798A publication Critical patent/JP2019524798A/ja
Publication of JP2019524798A5 publication Critical patent/JP2019524798A5/ja
Application granted granted Critical
Publication of JP7042254B2 publication Critical patent/JP7042254B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019506725A 2016-08-11 2017-08-07 近赤外光開裂性コンジュゲートおよびコンジュゲート前駆体 Active JP7042254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662373666P 2016-08-11 2016-08-11
US62/373,666 2016-08-11
PCT/US2017/045694 WO2018031448A1 (en) 2016-08-11 2017-08-07 Near-ir light-cleavable conjugates and conjugate precursors

Publications (3)

Publication Number Publication Date
JP2019524798A JP2019524798A (ja) 2019-09-05
JP2019524798A5 JP2019524798A5 (https=) 2020-07-30
JP7042254B2 true JP7042254B2 (ja) 2022-03-25

Family

ID=59656210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019506725A Active JP7042254B2 (ja) 2016-08-11 2017-08-07 近赤外光開裂性コンジュゲートおよびコンジュゲート前駆体

Country Status (4)

Country Link
US (2) US10561729B2 (https=)
EP (1) EP3496762A1 (https=)
JP (1) JP7042254B2 (https=)
WO (1) WO2018031448A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655408B1 (en) 2017-08-24 2021-07-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Conformational restriction of cyanine fluorophores in far-red and near-ir range
EP3752486A4 (en) * 2018-02-15 2022-07-06 Children's National Medical Center Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems
AU2019325658B2 (en) 2018-08-23 2024-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Water soluble novel cyanine fluorophore with tunable properties between near IR and SWIR region for in vivo imaging
WO2020179749A1 (ja) * 2019-03-05 2020-09-10 国立大学法人東海国立大学機構 標的特異的複合体及びその用途
US20210353151A1 (en) * 2020-05-12 2021-11-18 On Target Laboratories, LLC Targeted fluorescent markers in combination with a flexible probe
WO2022050376A1 (ja) * 2020-09-04 2022-03-10 国立大学法人東海国立大学機構 光を用いた薬物伝送方法、及び標的集積型複合体
JPWO2022163807A1 (https=) * 2021-01-29 2022-08-04
CN115433356B (zh) * 2022-03-11 2023-06-30 中国科学院精密测量科学与技术创新研究院 一种PEG修饰的氟化Cy7胶束及其合成方法和应用
CN114573645A (zh) * 2022-03-26 2022-06-03 常州大学 乳糖酸-新吲哚菁绿偶联物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1065250B1 (en) 1999-07-02 2004-12-08 Visen Medical, Inc. New fluorescent cyanine labels containing a sulfamido linker arm
US7198778B2 (en) 2000-01-18 2007-04-03 Mallinckrodt Inc. Tumor-targeted optical contrast agents
US7556797B2 (en) 2000-10-16 2009-07-07 Mallinckrodt Inc. Minimally invasive physiological function monitoring agents
US8188116B2 (en) 2002-09-04 2012-05-29 Vanderbilt University Agents for therapy efficacy monitoring and deep tissue imaging
US8227621B2 (en) 2005-06-30 2012-07-24 Li-Cor, Inc. Cyanine dyes and methods of use
US20080050316A1 (en) 2006-08-24 2008-02-28 Baylor College Of Medicine Molecular imaging of epithelial cells in lymph
WO2009012109A2 (en) 2007-07-13 2009-01-22 Emory University Cyanine-containing compounds for cancer imaging and treatment
WO2009023813A1 (en) 2007-08-15 2009-02-19 Applied Soil Water Technologies Llc Metals recovery from mining heap leach ore
JP5515529B2 (ja) 2009-09-04 2014-06-11 国立大学法人三重大学 近赤外光発光化合物、その合成法及びその発光法
SG184224A1 (en) 2010-03-24 2012-11-29 Univ Singapore Development of photostable near-ir cyanine dyes for in vivo imaging
WO2013036543A2 (en) 2011-09-10 2013-03-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
CN105339436B (zh) 2013-03-15 2018-05-25 文森医学公司 4,4-二取代环己基桥连七甲川花菁染料及其应用
WO2014149069A1 (en) 2013-03-15 2014-09-25 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
KR101494639B1 (ko) 2013-05-15 2015-02-23 고려대학교 산학협력단 엽산 Cy7계 치료진단용 약물 전달 시스템 및 이것의 제조방법
US10280307B2 (en) 2014-11-05 2019-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Class of stable heptamethine cyanine fluorophores and biomedical applications thereof
WO2017027721A1 (en) 2015-08-12 2017-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near-ir light-cleavable conjugates and conjugate precursors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Angewandte Chemie,International Edition，2015年，Vo.54,No.46，pp.13635-13638
Journal of the American Chemical Society，2013年，Vol.135，pp.11657-11662

Also Published As

Publication number Publication date
JP2019524798A (ja) 2019-09-05
EP3496762A1 (en) 2019-06-19
US20200121790A1 (en) 2020-04-23
WO2018031448A1 (en) 2018-02-15
US10561729B2 (en) 2020-02-18
US20190167793A1 (en) 2019-06-06
US10874739B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
JP7042254B2 (ja) 近赤外光開裂性コンジュゲートおよびコンジュゲート前駆体
US11707537B2 (en) Conformational restriction of cyanine fluorophores in far-red and near-IR range
JP7085633B2 (ja) ｉｎ ｖｉｖｏ画像化のための非凝集性ヘプタメチンシアニンフルオロフォア
JP7085995B2 (ja) 光免疫療法のための組成物、組み合わせおよび関連方法
WO2017027721A1 (en) Near-ir light-cleavable conjugates and conjugate precursors
JP2021535116A (ja) ｉｎ ｖｉｖｏ画像化のための近ＩＲおよびＳＷＩＲ領域の間で調整可能な特性を有する新規な水溶性シアニンフルオロフォア
CN109791107B (zh) 靶向ca ix的nir染料及其用途
JP6793122B2 (ja) 術中イメージング
CN110199195A (zh) Psma靶向的nir染料及其用途
CN105339436A (zh) 4，4-二取代环己基桥连七甲川花菁染料及其应用
CN115942958A (zh) 酞菁染料化合物、缀合物及其使用方法
CN101296927A (zh) 生物相容的含n,n-二取代磺酰胺的荧光染料标记
US20250144250A1 (en) Ph-sensitive fluorophores
JP7736259B2 (ja) 化合物、その製造方法、複合体および短波赤外蛍光剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220314

R150 Certificate of patent or registration of utility model

Ref document number: 7042254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250